Value-based Medicine

Ophthalmology

Volumn 115, Issue 11, 2008, Pages 2099-

  Kymes, Steven M ^a   Vollman, David ^a   Frick, Kevin D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB; RANIBIZUMAB;

COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; LETTER; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; RETINA MACULA AGE RELATED DEGENERATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; COST-BENEFIT ANALYSIS; FOVEA CENTRALIS; HEALTH STATUS; HUMANS; INJECTIONS; MACULAR DEGENERATION; MARKOV CHAINS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 54949129074     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.06.018     Document Type: Letter

References (4)

1. Brown M.M., Brown G.C., Brown H.C., and Peet J. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 115 (2008) 1039-1045
2. In: Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, New York
3. Gillick M.R. Medicare coverage for technological innovations: time for new criteria?. N Engl J Med 350 (2004) 2199-2203
4. Kourlas H., and Schiller D.S. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 28 (2006) 36-44